Antibody Discovery
Eurofins CALIXAR technology empowers clients to efficiently generate antibodies, nanobodies, or synthetic antibodies with enhanced efficiency for developing innovative antibodies by producing new antigens.
Best-in-class proteins for antibody discovery
High-quality, native, pure, stable and functional antigens for various antibody development approaches
Antigens serve as pivotal targets in the realm of antibody discovery, initiating immune responses critical for innovative diagnostic and therapeutic breakthroughs in medicine and biotechnology. Our commitment to preserving the structural and functional integrity of antigens allows for the precise development of conformational antibodies and nanobodies with therapeutic potential.
Our technology seamlessly integrates with immunizations, phage displays, yeast displays, and synthetic displays, facilitating antibody and nanobody discovery while offering deeper insights into antibody-antigen interactions and mechanism of action.
Ideal for drug biologists and antibody discovery scientists from pharmaceutical, biotech, and academic sectors, Eurofins CALIXAR's Antibody Discovery technology is designed to enhance the development and characterization of antibodies.
Furthermore, our use of patented technology ensures that each antibody and nanobody development project is tailored to meet specific needs and requirements.
Immunization
Immunization for antibody discovery is a method used in biomedical research to generate specific antibodies against target antigens. This technique involves injecting a specific antigen (a protein, peptide, or pathogen) into an animal, such as a mouse or rabbit.
The animal's immune system responds to this antigen by producing a variety of antibodies. These antibodies can then be collected, isolated, and studied for their ability to bind specifically to the target antigen. This process enables the development of therapeutic antibodies or research tools useful in the diagnosis and treatment of diseases.
Phage / Yeast Displays
Phage or yeast display for antibody discovery is a technique used in research to generate and identify antibodies specific to a given antigen. In phage display, DNA fragments encoding antibodies are fused to coat proteins of bacteriophages (bacterial viruses) and exposed to a diverse library of these fragments. Phages expressing antibodies specific to the target antigen are selected.
In yeast display, genes encoding antibodies are inserted into the yeast genome. The antibodies are expressed on the surface of the yeast, and the yeast is screened to identify those that bind specifically to the antigen of interest.
In both approaches, selected antibodies are then isolated, characterized, and used for therapeutic or diagnostic purposes. These techniques enable the generation of a wide range of antibodies and targeting specific antigens with high affinity, which is valuable for drug research and development.
Ribosome displays
Ribosome display is a powerful technique for the in vitro selection of peptides and proteins from large libraries. It allows the rapid generation of diverse libraries of fully-native recombinant proteins and subsequent screening for specific binding properties, such as antibody-antigen interactions. Using ribosome display for antibody discovery with fully-native recombinant proteins offers advantages in terms of library diversity, rapidity, and the ability to screen for functional properties directly. It is a versatile technique that has been successfully applied in various research areas, including therapeutic antibody development.
Antibody-dependent enhancement
Antibody-dependent enhancement (ADE) is a phenomenon in which antibodies, instead of neutralizing a virus, enhance its entry into host cells, leading to an increase in viral infection and replication. ADE has been observed in the context of certain viral infections, particularly with some members of the Flaviviridae family, such as dengue virus and Zika virus. It is important to note that ADE is not a universal feature of all viral infections or antibody responses.
Nanobody discovery
Nanobodies, derived from camelid immune responses, are discovered using fully-native recombinant proteins. After immunizing a camelid, antibody-encoding genes are isolated and cloned. By expressing these genes in vitro, a library of nanobodies is created. Through selection processes like phage or yeast display, nanobodies with high affinity and specificity for the target antigen are isolated. This approach ensures the discovered nanobodies maintain their natural structure, making them promising for therapeutic and diagnostic applications.
Get access to CALIXAR's Drug Discovery Technology
All of our clients get access to our proprietary technology and expertise (8 patent families, more than 28 publications).
The CALIXAR® platform applies patented technologies solely available for clients under particular contracts (license, co-development, and service).
You can leverage CALIXAR’s proprietary technology as well as other best-in-class membrane protein technology that are unobtainable in the market.
Secure and boost
your discovery programs
Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.
